Why in Hospital After Wedge Resection

Why in Hospital After ERAS VATS Wedge Resection

In the realm of lung surgery, video-assisted thoracoscopic surgery (VATS) offers distinct advantages, including shorter hospital stays, reduced pain, improved quality of life, and increased postoperative mobility when compared to thoracotomy. Additionally, the enhanced recovery after surgery (ERAS) protocol in lung surgery, characterized by a comprehensive, multidisciplinary approach, have streamlined postoperative recovery, resulting in early discharge and diminished postoperative complications. However, drawing from our extensive experience with fully implemented ERAS VATS for patients undergoing pulmonary lobectomy, we observed that approximately 45% of patients did not experience early discharge.

Based on existing evidence, the length of stay (LOS) following wedge resection typically ranges from 3 to 6 days across various regions, including Europe, the United States, and China. However, there is a notable lack of procedure-specific data for ERAS VATS wedge resection to explore reasons of delaying discharge. This prompts us to undertake an investigation into individuals following pulmonary wedge resection under the same ERAS programs.

Study Overview

• Status: Completed
• Conditions: Enhanced Recovery After Surgery; Thoracic Surgery, Video-Assisted

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

• Study Contact: Name: Lin Huang; Phone Number: +4531478812; Email: lin.huang@regionh.dk
• Study Contact Backup: Name: René H Petersen; Phone Number: +4526494949; Email: Rene.Horsleben.Petersen@regionh.dk

Study Locations

• Denmark
  • Copenhagen, Denmark, 2100
    • Rigshospitalet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent video-assisted thoracoscopic surgery wedge resection.

Description

Inclusion Criteria:

• Patients who underwent video-assisted thoracoscopic surgery wedge resection

Exclusion Criteria:

• < 18 year old
• Unable to understand Danish
• No residence in the Eastern Denmark
• Transfer to anatomical resection or cancel surgery
• Reject to join or withdraw from the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of stay	Number of overnight stay	Up to the day of discharge
Reasons for staying in hospital	patient-reported outcomes for why in hospital, including pain or social factors; postoperative complications, diagnosed by clinicians	Up to the day of discharge

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of chest drain	Days of chest drain placed	Up to the day of chest drain removed
Postoperative complications	Diagonosis is following ICD-10	Up to postoperative day 30
30-day readmissions	Admission to hospital again within 30 days after surgery	Up to postoperative day 30
Postoperative pain scale	The pain scale (from 0 to 10) will be evaluated by patients.	At the day of surgery
Postoperative activity	Patients report whether they can stand up, walk within 6 meters, or walk over 6 meters, up to 3 and 6 hours after surgery	At the day of surgery
Opioid usage	It is classified as opioid used and no opioid used	At the day of surgery and at the day of discharge

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Investigators: Study Director: René H Petersen, Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2022
• Primary Completion (Actual): January 28, 2024
• Study Completion (Actual): January 28, 2024

Study Registration Dates

• First Submitted: November 1, 2023
• First Submitted That Met QC Criteria: November 1, 2023
• First Posted (Actual): November 7, 2023

Study Record Updates

• Last Update Posted (Estimated): February 6, 2024
• Last Update Submitted That Met QC Criteria: February 3, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: P-2022-238

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: The data is possible shared to other researchers if they contact with study director and the approvals are obtained subsequently.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No